112 related articles for article (PubMed ID: 3052135)
1. Orphan drugs. Improved medical treatment of rare diseases.
Cramer R
Ala J Med Sci; 1988 Jul; 25(3):257-67. PubMed ID: 3052135
[No Abstract] [Full Text] [Related]
2. [Orphan drugs--medications for patients with rare diseases].
Thielke D; Thyssen JP; Hansen BJ
Ugeskr Laeger; 2006 Jun; 168(23):2236-8. PubMed ID: 16768975
[TBL] [Abstract][Full Text] [Related]
3. Orphan drug development in the United States.
Groft SC
CPJ; 1985 May; 118(5):219-22. PubMed ID: 10271306
[TBL] [Abstract][Full Text] [Related]
4. Orphan drug development for the treatment of rare chronic diseases.
Moore ES
Tex Hosp; 1988 Jul; 44(2):20-1. PubMed ID: 10288218
[No Abstract] [Full Text] [Related]
5. Rare diseases, orphan drugs, and orphaned patients.
Scheindlin S
Mol Interv; 2006 Aug; 6(4):186-91. PubMed ID: 16960139
[No Abstract] [Full Text] [Related]
6. Orphan drugs: the question of products liability.
Scharf SF
Am J Law Med; 1985; 10(4):491-513. PubMed ID: 3911776
[TBL] [Abstract][Full Text] [Related]
7. Lucrative niches: how drugs for rare diseases became lifeline for companies.
Anand G
Wall St J (East Ed); 2005 Nov; ():A1, A18. PubMed ID: 16502531
[No Abstract] [Full Text] [Related]
8. The Pharmaceutical Manufacturers Association Commission on Drugs for Rare Diseases.
Goldstein GS
Prog Clin Biol Res; 1985; 197():35-9. PubMed ID: 4070297
[No Abstract] [Full Text] [Related]
9. Orphan Drug Act on congressional agenda.
von Oehsen WH
Physician Exec; 1989; 15(3):34-5. PubMed ID: 10313123
[TBL] [Abstract][Full Text] [Related]
10. Rare diseases, drug development, and AIDS: the impact of the Orphan Drug Act.
Arno PS; Bonuck K; Davis M
Milbank Q; 1995; 73(2):231-52. PubMed ID: 7776947
[TBL] [Abstract][Full Text] [Related]
11. Rare diseases: identifying needs. Report of the National Commission on Orphan Diseases.
Groft SC
Am Pharm; 1990 Apr; NS30(4):33-40. PubMed ID: 2321528
[No Abstract] [Full Text] [Related]
12. [Orphan drugs].
Kolár J; Chalabala M; Srámková H
Ceska Slov Farm; 2001 Mar; 50(2):59-65. PubMed ID: 11288591
[TBL] [Abstract][Full Text] [Related]
13. The fuel to run the orphan drug engine: a medical school-based Orphan Disease Center Program.
Brewer GJ
Prog Clin Biol Res; 1985; 197():123-38. PubMed ID: 4070287
[No Abstract] [Full Text] [Related]
14. Problems associated with developing orphan drugs into available therapy.
Van Woert MH
Prog Clin Biol Res; 1985; 197():171-3. PubMed ID: 4070291
[No Abstract] [Full Text] [Related]
15. Orphan Drugs Information Center.
FDA Drug Bull; 1985 Apr; 15(1):9-10. PubMed ID: 3996806
[No Abstract] [Full Text] [Related]
16. Drugs for rare diseases: mixed assessment in Europe.
Prescrire Int; 2007 Feb; 16(87):36-42. PubMed ID: 17323539
[TBL] [Abstract][Full Text] [Related]
17. [Orphan drugs: some legal, ethical and economics aspects].
Pabst JY
Rev Epidemiol Sante Publique; 2001 Sep; 49(4):387-96. PubMed ID: 11567205
[TBL] [Abstract][Full Text] [Related]
18. The development of orphan drugs--a pharmaceutical company perspective.
Stucki JC
Prog Clin Biol Res; 1985; 197():95-104. PubMed ID: 4070303
[No Abstract] [Full Text] [Related]
19. National Orphan Drugs and Devices Foundation.
Bennett J
Prog Clin Biol Res; 1985; 197():47-9. PubMed ID: 4070299
[No Abstract] [Full Text] [Related]
20. Orphan products development and some methods for maximizing the usefulness of research on rare diseases.
Finkel MJ
Prog Clin Biol Res; 1985; 197():11-8. PubMed ID: 4070285
[No Abstract] [Full Text] [Related]
[Next] [New Search]
